Colorectal cancer (CRC) is the third most commonly diagnosed malignancy worldwide and remains a major public health issue. Therefore, further investigation is required to delineate the cellular and molecular mechanisms underlying colorectal tumorigenesis. Using CRC data taken from The Cancer Genome Atlas, we determined that the expression of otopetrin 2 (OTOP2) is highly correlated with malignancy grade and rate of patient survival. Here, we report that OTOP2 is down-regulated in cancerous tissues and that elevated OTOP2 effectively suppresses tumor proliferation . We demonstrate that wild-type p53 (wtp53), but not mutant p53 (mtp53), can regulate the transcription of in CRC cells. Subsequently, we investigate the chromatin architecture of the promoter, whereby we discover alterations in p53-dependent DNA loop organization and CCCTC-binding factor (CTCF) binding between cells with wtp53 and mtp53. In conclusion, our study promotes an in-depth understanding of tumorigenesis, which may also lead to the development of therapeutic applications targeting human malignancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325572PMC
http://dx.doi.org/10.1002/2211-5463.12554DOI Listing

Publication Analysis

Top Keywords

wild-type p53
8
dna loop
8
colorectal cancer
8
p53 regulates
4
otop2
4
regulates otop2
4
otop2 transcription
4
transcription dna
4
loop alteration
4
alteration promoter
4

Similar Publications

Molecular Mechanisms of Synergistic Effect of PRIMA-1 and Oxaliplatin in Colorectal Cancer With Different p53 Status.

Cancer Med

January 2025

Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, People's Republic of China.

Background: The toxicity and drug resistance associated with oxaliplatin (L-OHP) limit its long-term use for colorectal cancer (CRC) patients. p53 mutation is a common genetic trait of CRC. PRIMA-1 (APR-246, eprenetapopt) restores the DNA-binding capacity of different mutant P53 proteins.

View Article and Find Full Text PDF

Objective: To explore the effect of mutation variant allele frequency(VAF) on the prognosis of diffuse large B-cell lymphoma(DLBCL) patients.

Methods: This study included 155 patients with DLBCL who were first diagnosed in the People's Hospital of Xinjiang Uygur Autonomous Region from March 2009 to March 2022. Complete clinical data and paraffin-embedded tumor tissue samples were obtained, and DNA was extracted from tumor tissues.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer, lacking effective targeted therapies and presenting with a poor prognosis. In this study, we utilized the epigenomic landscape, TCGA database, and clinical samples to uncover the pivotal role of HJURP in TNBC. Our investigation revealed a strong correlation between elevated HJURP expression and unfavorable prognosis, metastatic progression, and late-stage of breast cancer.

View Article and Find Full Text PDF

MicroRNAs (miRNAs) play a significant role in tumor progression, and regulating miRNA expression with small molecules may offer a new approach to cancer therapy. Among them, miRNA-20b has been found to be dysregulated in several cancers, including nonsmall cell lung cancer (NSCLC). Herein, an in silico high-throughput computer screen was conducted to identify small molecules that downregulate miR-20b using the three-dimensional structure of the Dicer binding site on pre-miR-20b.

View Article and Find Full Text PDF

To investigate the functional role of S100A4 in advanced colorectal carcinoma (Ad-CRC) and locally advanced rectal carcinoma (LAd-RC) receiving neoadjuvant chemoradiotherapy (NCRT). We analyzed histopathological and immunohistochemical sections from 150 patients with Ad-CRC and 177 LAd-RC patients treated with NCRT. S100A4 knockout (KO) HCT116 cells were also used.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!